Cargando…

Role of Anti-MICA Antibodies in Graft Survival of Renal Transplant Recipients of India

INTRODUCTION: The MIC (MHC class I chain-related) genes are a group of nonclassical MHC genes, located in the MHC class 1 region of chromosome 6. The aim of the present study was to find the prevalence of MHC class 1 chain-related (MICA) alloantibodies in patients undergoing live-related donor renal...

Descripción completa

Detalles Bibliográficos
Autores principales: Chowdhry, Mohit, Makroo, R. N., Singh, Mandhata, Kumar, Manoj, Thakur, Yogita, Sharma, Vandana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5907422/
https://www.ncbi.nlm.nih.gov/pubmed/29850626
http://dx.doi.org/10.1155/2018/3434050
_version_ 1783315529228877824
author Chowdhry, Mohit
Makroo, R. N.
Singh, Mandhata
Kumar, Manoj
Thakur, Yogita
Sharma, Vandana
author_facet Chowdhry, Mohit
Makroo, R. N.
Singh, Mandhata
Kumar, Manoj
Thakur, Yogita
Sharma, Vandana
author_sort Chowdhry, Mohit
collection PubMed
description INTRODUCTION: The MIC (MHC class I chain-related) genes are a group of nonclassical MHC genes, located in the MHC class 1 region of chromosome 6. The aim of the present study was to find the prevalence of MHC class 1 chain-related (MICA) alloantibodies in patients undergoing live-related donor renal transplantation and its role in short-term graft survival. The role of blood transfusion in the formation of these antibodies was also studied. MATERIALS AND METHODS: Pretransplant samples of patients undergoing renal allograft transplantation were tested for anti-MICA antibodies. Association of various demographics, HLA-A + B + DRB1 mismatches, anti-HLA antibody screen, and anti-MICA antibodies was assessed using Pearson's chi-square test. RESULTS: Out of 646 serum samples, 94 (14.6%) were positive and 552 (85.4%) were negative for anti-MICA antibodies. Patients with anti-MICA antibody had a graft survival 89.3% as compared to 94.7% in patients without anti-MICA antibody (P < 0.05). The hazard ratio for all patients was 3.0701 (P < 0.05). Out of the 340 patients with no HLA antibodies, the presence of anti-MICA antibodies without any HLA antibodies (n = 43) was associated with poor outcome in the patients (hazard ratio of 2.768, P < 0.05). The presence of MICA antibodies with HLA antibodies did not decrease the graft survival (hazards ratio of 1.3750, P > 0.05). CONCLUSION: Preformed MICA antibodies independently increase the risk of kidney rejection and therefore recommend that guidelines should be formed for mandatory testing of these antibodies prior to renal transplant.
format Online
Article
Text
id pubmed-5907422
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-59074222018-05-30 Role of Anti-MICA Antibodies in Graft Survival of Renal Transplant Recipients of India Chowdhry, Mohit Makroo, R. N. Singh, Mandhata Kumar, Manoj Thakur, Yogita Sharma, Vandana J Immunol Res Research Article INTRODUCTION: The MIC (MHC class I chain-related) genes are a group of nonclassical MHC genes, located in the MHC class 1 region of chromosome 6. The aim of the present study was to find the prevalence of MHC class 1 chain-related (MICA) alloantibodies in patients undergoing live-related donor renal transplantation and its role in short-term graft survival. The role of blood transfusion in the formation of these antibodies was also studied. MATERIALS AND METHODS: Pretransplant samples of patients undergoing renal allograft transplantation were tested for anti-MICA antibodies. Association of various demographics, HLA-A + B + DRB1 mismatches, anti-HLA antibody screen, and anti-MICA antibodies was assessed using Pearson's chi-square test. RESULTS: Out of 646 serum samples, 94 (14.6%) were positive and 552 (85.4%) were negative for anti-MICA antibodies. Patients with anti-MICA antibody had a graft survival 89.3% as compared to 94.7% in patients without anti-MICA antibody (P < 0.05). The hazard ratio for all patients was 3.0701 (P < 0.05). Out of the 340 patients with no HLA antibodies, the presence of anti-MICA antibodies without any HLA antibodies (n = 43) was associated with poor outcome in the patients (hazard ratio of 2.768, P < 0.05). The presence of MICA antibodies with HLA antibodies did not decrease the graft survival (hazards ratio of 1.3750, P > 0.05). CONCLUSION: Preformed MICA antibodies independently increase the risk of kidney rejection and therefore recommend that guidelines should be formed for mandatory testing of these antibodies prior to renal transplant. Hindawi 2018-04-05 /pmc/articles/PMC5907422/ /pubmed/29850626 http://dx.doi.org/10.1155/2018/3434050 Text en Copyright © 2018 Mohit Chowdhry et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Chowdhry, Mohit
Makroo, R. N.
Singh, Mandhata
Kumar, Manoj
Thakur, Yogita
Sharma, Vandana
Role of Anti-MICA Antibodies in Graft Survival of Renal Transplant Recipients of India
title Role of Anti-MICA Antibodies in Graft Survival of Renal Transplant Recipients of India
title_full Role of Anti-MICA Antibodies in Graft Survival of Renal Transplant Recipients of India
title_fullStr Role of Anti-MICA Antibodies in Graft Survival of Renal Transplant Recipients of India
title_full_unstemmed Role of Anti-MICA Antibodies in Graft Survival of Renal Transplant Recipients of India
title_short Role of Anti-MICA Antibodies in Graft Survival of Renal Transplant Recipients of India
title_sort role of anti-mica antibodies in graft survival of renal transplant recipients of india
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5907422/
https://www.ncbi.nlm.nih.gov/pubmed/29850626
http://dx.doi.org/10.1155/2018/3434050
work_keys_str_mv AT chowdhrymohit roleofantimicaantibodiesingraftsurvivalofrenaltransplantrecipientsofindia
AT makroorn roleofantimicaantibodiesingraftsurvivalofrenaltransplantrecipientsofindia
AT singhmandhata roleofantimicaantibodiesingraftsurvivalofrenaltransplantrecipientsofindia
AT kumarmanoj roleofantimicaantibodiesingraftsurvivalofrenaltransplantrecipientsofindia
AT thakuryogita roleofantimicaantibodiesingraftsurvivalofrenaltransplantrecipientsofindia
AT sharmavandana roleofantimicaantibodiesingraftsurvivalofrenaltransplantrecipientsofindia